Results 11 to 20 of about 7,935 (218)
Pharmacogenetic studies of thiopurines : focus on thiopurine methyltransferase
, 2005 Pharmacogenetics represents the study ofvariability in drug response due to genetic variations. The thiopurines (6-mercaptopurine, 6-thioguanine and azathioprine) are prodrugs which require metabolic transformation to exert effect. Thiopurines are used in inflammatory bowel disease, as maintenance treatment of childhood acute lymphoblastic leukaemia ...
Lindqvist Appell, Malin
core +4 more sources
Pharmacogenetics of thiopurines
, 2008 The thiopurines (mercaptopurine, azathioprine and thioguanine) have been highly successful drugs, heralding the era of organ transplantation, providing maintenance therapy in the treatment of leukemias,1 and proving useful for treating chronic inflammatory and autoimmune conditions (see: Chapter 38).2,3 Overall, the therapeutic success rate for ...
Oancea, I., Duley, J. A.
openaire +2 more sources
The Thiopurine Tale: An Unexpected Journey [PDF]
Journal of Crohn's and Colitis, 2022 Abstract Exactly 70 years ago [1951] mercaptopurine was discovered by Gertrude Elion as a novel treatment option for acute leukaemia. A total of three thiopurines (also thioguanine [1950] and azathioprine [1957]) were developed over time.
Femke Crouwel +2 more
openaire +3 more sources
Pharmacogenetics and Genomics, 2010 The thiopurine drugs are purine antimetabolites widely used in the treatment of acute lymphoblastic leukemia, autoimmune disorders (e.g. Crohn’s disease and rheumatoid arthritis) and of organ transplant recipients. As inactive prodrugs, 6-mercaptopurine (6-MP), 6-thioguanine (6-TG) and azathioprine require intracellular activation, catalyzed by ...
Gianluigi Zaza +11 more
openaire +7 more sources
Pharmacogenomic tests of oncology drugs at Instituto Nacional de Câncer (INCA)
Brazilian Journal of Oncology, 2021 The implementation, current status and future perspectives of the pharmacogenetics/genomics (PGx) testing program developed at Instituto Nacional de Cancer (INCA) are presented. Initial selection of drug-gene pairs for PGx testing was based on clinically-
Guilherme Suarez-Kurtz
doaj +1 more source
Squamous cell carcinoma and Crohn's disease: a sometimes-challenging diagnosis
Future Science OA, 2023 Aim: Non-melanoma skin cancers are more common in people with inflammatory bowel disease. However, these tumors can rarely mimic a cutaneous manifestation of the disease, which delays diagnosis and clouds prognosis.
Mona Boudabbous +9 more
doaj +1 more source
Can We Predict the Toxicity and Response to Thiopurines in Inflammatory Bowel Diseases?
Frontiers in Medicine, 2019 Thiopurines are a cheap, effective treatment option in the management of inflammatory bowel disease (IBD). However, with the growing choice of targeted therapies available, as well as the well-documented toxicities of thiopurines, the role of thiopurines
Raphael P. Luber +3 more
doaj +1 more source
Use of thiopurines and risk of colorectal neoplasia in patients with inflammatory bowel diseases: a meta-analysis. [PDF]
PLoS ONE, 2013 ObjectiveInflammatory bowel disease (IBD) is commonly treated with thiopurines such as azathioprine and mercaptopurine for the maintenance of remission.
Jianfeng Gong +6 more
doaj +1 more source
Metabolites, 2022 Thiopurine drugs are part of the therapeutic armamentarium for pediatric patients suffering from inflammatory bowel disease (IBD) and acute lymphoblastic leukemia (ALL).
Martina Franzin +8 more
doaj +1 more source
Long-term efficacy and tolerability of dose-adjusted thiopurine treatment in maintaining remission in inflammatory bowel disease patients with heterozygosity [PDF]
Intestinal Research, 2022 Background/Aims Thiopurines are key drugs for inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn’s disease (CD). Recently, NUDT15 polymorphism (R139C, c.415C > T) has been shown to be associated with thiopurine-induced adverse ...
Takato Maeda +11 more
doaj +1 more source